Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES2 | Q9H7Z7 | 4/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ACLY | P53396 | 2/20 | 0.42 |
| ▸ | CCR2 | P41597 | 2/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1817827 | 0.81 | PTGES2 (0.49) | PTGES2CYP3A4POLBKMT2APTK2B | |
| SCHEMBL1818665 | 0.80 | PTGES2 (0.48) | PTGES2CYP3A4POLBKMT2APTK2B | |
| SCHEMBL25450035 | 0.78 | MCL1 (0.61) | PTGES2ACLYCCR2 | |
| SCHEMBL16263833 | 0.77 | SLC40A1 (0.52) | PTGES2CCR2SLC40A1 | |
| SCHEMBL29721254 | 0.77 | CYP3A4 (0.52) | PTGES2CYP3A4SMN1; SMN2ACLYBRAF | |
| SCHEMBL29721313 | 0.77 | CYP3A4 (0.52) | PTGES2CYP3A4SMN1; SMN2ACLYBRAF | |
| SCHEMBL1127184 | 0.77 | CYP3A4 (0.52) | PTGES2CYP3A4SMN1; SMN2ACLYBRAF | |
| SCHEMBL27830664 | 0.77 | PTGES2 (0.48) | PTGES2CYP3A4KMT2APTK2BSMN1; SMN2 | |
| SCHEMBL3020003 | 0.77 | PTGES2 (0.53) | PTGES2CYP3A4ACLYCCR2BRAF | |
| SCHEMBL30161625 | 0.77 | PTGES2 (0.50) | PTGES2CYP3A4POLBKMT2AACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2678336-B1 | THIAZOLYLPHENYL-BENZENESULFONAMIDO DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-04-20 | — | — | EP | disclosed |
| US-9199979-B2 | Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-12-01 | — | — | US | disclosed |
| EP-2601185-B1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2015-10-07 | — | — | EP | disclosed |
| EP-2601185-B1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2015-10-07 | — | — | EP | disclosed |
| US-9114137-B2 | Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-08-25 | — | — | US | disclosed |
| US-9114137-B2 | Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-08-25 | — | — | US | disclosed |
| EP-2678336-A1 | THIAZOLYLPHENYL-BENZENESULFONAMIDO DERIVATIVES AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2014-01-01 | — | — | EP | disclosed |
| US-20130324551-A1 | THIAZOLYLPHENYL-BENZENESULFONAMIDO DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-12-05 | — | — | US | disclosed |
| US-20130217715-A1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | LSI FINANCING 1 DESIGNATED ACTIVITY COMPANY (IE) | 2013-08-22 | — | — | US | disclosed |
| US-20130217715-A1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | LSI FINANCING 1 DESIGNATED ACTIVITY COMPANY (IE) | 2013-08-22 | — | — | US | disclosed |
| EP-2601185-A1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | Nerviano Medical Sciences S.r.l. (IT) | 2013-06-12 | — | — | EP | disclosed |
| WO-2012113774-A1 | THIAZOLYLPHENYL-BENZENESULFONAMIDO DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-08-30 | — | — | WO | disclosed |
| WO-2012016993-A1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217715-A1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | CDK2, CDK1, CDK4 | PTGES2 3332/4885CYP3A4 3639/4885POLB 1281/4885 |
| US-20130324551-A1 | THIAZOLYLPHENYL-BENZENESULFONAMIDO DERIVATIVES AS KINASE INHIBITORS | MAP3K6, MAP3K1, MAP3K5 | PTGES2 2774/4885CYP3A4 2826/4885POLB 2561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.